natgillin/translations-raw huggingface dataset:
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, acetylsalicylic acid, statins, fibrates). 
Gotovo su svi bolesnici (95%) primali kardiovaskularne lijekove (beta blokatore, inhibitore angiotenzin-konvertirajućeg enzima (ACE), antagoniste angiotenzina II, blokatore kalcijevih kanala, nitrate, diuretike, acetilsalicilatnu kiselinu, statine, fibrate).
See section 2 “Actos contains lactose monohydrate”. 
Pogledajte dio 2 „Actos sadrži laktozu hidrat“.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Actos. 
Ako Vam je liječnik rekao da ne podnosite neke šećere, obratite se liječniku prije nego što uzmete Actos.
The other side effects that have been experienced by some patients when Actos is taken with other antidiabetic medicines are: 
Druge nuspojave koje su neki bolesnici osjetili kod uzimanja lijeka Actos s drugim antidijabetičkim lijekovima su:
Takeda Pharma A/S Dybendal Alle 10 DK-2630 Taastrup Denmark 
Takeda Pharma A/S Dybendal Alle 10 DK-2630 Taastrup Danska
very common (may affect more than 1 in 10 people) - decreased blood sugar (hypoglycaemia) 
vrlo često (mogu se pojaviti kod više od 1 na 10 osoba) - snižen šećer u krvi (hipoglikemija)
- you are breast-feeding or if you are planning to breast-feed your baby. 
- ako dojite ili planirate dojiti svoje dijete.
If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy. 
Ako se to odnosi na Vas, koristite odgovarajuću kontracepciju kako biste izbjegli mogućnost neplanirane trudnoće. - ako imate tegobe s jetrom ili srcem.
If ALT levels remain > 3 x the upper limit of normal, therapy should be discontinued. 
Ako razine ALT ostanu povišene više od 3 puta iznad gornje granice normale, terapiju treba prekinuti.
Pioglitazone is contraindicated in patients with: 
Pioglitazon je kontraindiciran u bolesnika s:
You can usually continue to take other medicines whilst you are being treated with Actos. 
Za vrijeme liječenja lijekom Actos obično možete nastaviti uzimati druge lijekove.
Actos may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar. 
Actos se može primjenjivati sam u bolesnika koji ne mogu uzimati metformin, a kod kojih se liječenjem dijetom i tjelovježbom nije uspjela postići kontrola šećera u krvi, ili se može dodati drugim lijekovima (kao što su metformin, sulfonilureja ili inzulin) koji nisu uspjeli osigurati dostatnu kontrolu šećera u krvi.
How to take Actos 
Kako uzimati Actos
Environmental Risk Assessment (ERA): No environmental impact is anticipated from the clinical use of pioglitazone. 
Procjena rizika za okoliš (ERA): Ne očekuje se utjecaj na okoliš tijekom kliničke primjene pioglitazona.
Your blood sugar will be checked, and your dose of Actos may need to be changed. 
Provjerit će Vam šećer u krvi i nakon toga možda promijeniti dozu lijeka Actos.
At two years, glycaemic control (defined as HbA1c < 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide. 
Nakon dvije godine, kontrola glikemije (definirana kao HbA1c < 8,0%) bila je održana u 69% bolesnika liječenih pioglitazonom u odnosu na 50% bolesnika koji su uzimali gliklazid.
Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 x upper limit of normal) or with any other evidence of liver disease. 
Terapija pioglitazonom ne smije se započeti u bolesnika s povišenim početnim razinama jetrenih enzima (ALT više od 2,5 puta iznad gornje granice normale) ili nekim drugim dokazom bolesti jetre.
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments. 
Poremećaj vida zabilježen je uglavnom rano tijekom liječenja i povezan s promjenama glukoze u krvi zbog privremene promjene u turgoru i indeksu loma leće kakav se vidi i kod druge hipoglikemijske terapije.
When Actos is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines. 
Kad se Actos uzima zajedno s drugim lijekovima za liječenje šećerne bolesti (kao što su inzulin, klorpropamid, glibenklamid, gliklazid, tolbutamid) liječnik će Vam reći trebate li te lijekove uzimati u manjim dozama.
Eli Lilly Holdings Limited atstovybė 
Eli Lilly Holdings Limited atstovybė Tel.
You may take your tablets with or without food. 
Actos s hranom i pićem Tablete možete uzimati s hranom ili bez nje.
Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03. 
Farmakoterapijska skupina: Pripravci za liječenje šećerne bolesti; oralni lijekovi za snižavanje glukoze u krvi, osim inzulina; ATK oznaka: A10BG03.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, p=0.029). 
U meta-analizi kontroliranih kliničkih ispitivanja češće su zabilježeni slučajevi karcinoma mokraćnog mjehura u skupinama koje su primale pioglitazon (19 slučajeva na 12 506 bolesnika, 0,15%) nego u kontrolnim skupinama (7 slučajeva na 10 212 bolesnika, 0,07%) HR = 2,64 (95% CI 1,11-6,31, p = 0,029).
Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 and 196 tablets. 
Aluminij/aluminij blisteri, pakiranja od 14, 28, 30, 50, 56, 84, 90, 98, 112 i 196 tableta.
Post-marketing, bone fractures have been reported in both male and female patients (see section 4.4) 
Nakon stavljanja lijeka u promet, prijavljeni su prijelomi kostiju i kod muških i kod ženskih bolesnika (vidjeti dio 4.4).
It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus in adults, when metformin is not suitable or has failed to work adequately. 
To je antidijabetički lijek koji se primjenjuje za liječenje šećerne bolesti tipa 2 (neovisne o inzulinu) kod odraslih, kad metformin nije pogodan ili nije imao odgovarajuće djelovanje.
− The other ingredients are lactose monohydrate, hyprolose, carmellose calcium and magnesium stearate. 
Drugi sastojci su laktoza hidrat, hiproloza, karmelozakalcij i magnezijev stearat.
Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. 
Pioglitazon vjerojatno djeluje putem aktivacije posebnih receptora u jezgri (receptor gama aktiviran peroksizomskim proliferatorom - PPAR gama), što u životinja dovodi do povećane osjetljivosti jetre, masnog tkiva i skeletnih mišića na inzulin.
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 mL/min) (see section 5.2). 
Nije potrebna prilagodba doze u bolesnika s oštećenom funkcijom bubrega (klirens kreatinina > 4 ml/min) (vidjeti dio 5.2).
Actos tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. 
Tablete Actos sadrže laktozu hidrat te se stoga ne smiju primjenjivati u bolesnika s rijetkim nasljednim poremećajima nepodnošenja galaktoze, potpunim nedostatkom laktaze ili malapsorpcijom glukoze i galaktoze.
The tablets are supplied in blister packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 or 196 tablets. 
Tablete se isporučuju u blisterima s 14, 28, 30, 50, 56, 84, 90, 98, 112 ili 196 tableta.
This leaflet was last approved in Other sources of information 
Ova uputa je zadnji puta odobrena u
Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Budući da postoji mogućnost povećanja nuspojava povezanih s dozom, možda bude potrebno sniziti dozu pioglitazona kod istodobne primjene gemfibrozila.
Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking Actos and have also been reported in male patients (frequency cannot be estimated from the available data) taking Actos. 
Prijelomi kostiju su često prijavljivani (mogu se pojaviti u do 1 na 10 osoba) u žena koje su uzimale Actos, a također su prijavljivani i u muškaraca (učestalost se ne može procijeniti iz dostupnih podataka) koji su uzimali Actos.
Your doctor will take this into account when treating your diabetes. 
Liječnik koji Vas liječi zbog šećerne bolesti to će uzeti u obzir.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4). 
Pioglitazon je također indiciran u kombinaciji s inzulinom u odraslih bolesnika sa šećernom bolešću tipa 2 i nedostatnom kontrolom glikemije pomoću inzulina u kojih je metformin neprikladan zbog kontraindikacija ili nepodnošljivosti (vidjeti dio 4.4).
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite 
često (mogu se pojaviti u do 1 na 10 osoba) - glavobolja - omaglica - bol u zglobovima - impotencija - križobolja - nedostatak zraka - malo sniženje broja crvenih krvnih stanica - nadutost manje često (mogu se pojaviti u do 1 na 100 osoba) - šećer u mokraći, proteini u mokraći - povišenje enzima - osjećaj vrtnje (vrtoglavica) - znojenje - umor - pojačan apetit
Hepatic impairment Pioglitazone should not be used in patients with hepatic impairment (see sections 4.3 and 4.4). 
Pioglitazon se ne smije primjenjivati u bolesnika s oštećenjem jetre (vidjeti dio 4.3 i 4.4).
Actos contains lactose monohydrate 
Actos sadrži laktozu hidrat
Kaplan-Meier analysis showed shorter time to treatment failure in patients treated with gliclazide, compared with pioglitazone. 
Kaplan-Meierovom analizom pokazalo se da je vrijeme do prestanka odgovora na terapiju u bolesnika liječenih gliklazidom kraće nego kod liječenja pioglitazonom.
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. 
kao monoterapija - u odraslih bolesnika (osobito bolesnika s prekomjernom tjelesnom težinom) u kojih se kontrola ne postiže dijetom i tjelovježbom i u kojih metformin nije prikladan zbog kontraindikacija ili nepodnošenja kao dvojna peroralna terapija u kombinaciji s - metforminom, u odraslih bolesnika (osobito bolesnika s prekomjernom tjelesnom težinom) s nedostatnom kontrolom glikemije usprkos monoterapiji metforminom u najvećoj podnošljivoj dozi - sulfonilurejom, samo u odraslih bolesnika s nepodnošenjem metformina ili u kojih je metformin kontraindiciran, s nedostatnom kontrolom glikemije usprkos monoterapiji sulfonilurejom u najvećoj podnošljivoj dozi.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin. 
U ispitivanju ishoda u bolesnika s postojećom teškom makrovaskularnom bolešću, incidencija ozbiljnog zatajenja srca bila je 1,6% viša uz pioglitazon nego uz placebo kad se pioglitazon dodao terapiji koja je uključivala inzulin.
as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. 
kao trojna peroralna terapija u kombinaciji s - metforminom i sulfonilurejom, u odraslih bolesnika (osobito bolesnika s prekomjernom tjelesnom težinom) s nedostatnom kontrolom glikemije usprkos dvojnoj peroralnoj terapiji.
Your doctor will ask you to have blood tests periodically during treatment with Actos. 
Liječnik će tražiti da za vrijeme liječenja lijekom Actos povremeno napravite krvne pretrage, da bi se provjerilo radi li Vaša jetra normalno.
de la Industria 30, 28108 Alcobendas (Madrid), Spain 
Lilly S.A, Avda. de la Industria 30, 28108 Alcobendas (Madrid), Španjolska
If ALT levels are increased to 3 x upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible. 
Ako se tijekom terapije pioglitazonom razine ALT povise na vrijednosti koje su 3 puta iznad gornje granice normale, razine jetrenih enzima treba čim prije ponovno provjeriti.
- hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - cardiac failure or history of cardiac failure (NYHA stages I to IV) - hepatic impairment - diabetic ketoacidosis - current bladder cancer or a history of bladder cancer - uninvestigated macroscopic haematuria 
- preosjetljivošću na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1 - zatajenjem srca ili anamnezom zatajenja srca (NYHA stadiji I do IV) - oštećenjem funkcije jetre - dijabetičkom ketoacidozom - postojećim ili preboljenim karcinomom mokraćnog mjehura - neispitanom makroskopskom hematurijom.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Actos and insulin experienced the development of heart failure. 
U nekih bolesnika koji su dugo imali šećernu bolest tipa 2 i srčanu bolest ili su preboljeli moždani udar a liječili su se lijekom Actos i inzulinom došlo je do zatajenja srca.
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. 
Nuspojave koje su bile zabilježene češće (> 0,5%) nego uz placebo ili kao izolirani slučaj u bolesnika koji su primali pioglitazon u dvostruko slijepim ispitivanjima navedene su niže prema MedDRA pojmovima, klasifikaciji organskih sustava i apsolutnoj učestalosti.
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels. 
U većini kliničkih ispitivanja primijećeno je sniženje ukupnih triglicerida i slobodnih masnih kiselina u plazmi te povišenje razine HDL-kolesterola u usporedbi s placebom, uz mala ali ne i klinički značajna povišenja razine LDL-kolesterola.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Actos. 
Kad uzimate Actos, možete ponovno imati ovulaciju pa mogućnost trudnoće može biti povećana.
Musculoskeletal and connective tissue disorders fracture bone4 
Poremećaji mišićnokoštanog sustava i vezivnog tkiva prijelom kosti4
Takeda UK Ltd Tel: +44 (0)1628 537 900 
United Kingdom Takeda UK Ltd Tel: + 44 (0)1628 537 900
Localised swelling (oedema) has also been experienced very commonly (may affect more than 1 in 10 people) in patients taking Actos in combination with insulin. 
Lokalizirano oteknuće (edemi) također su vrlo često (mogu se pojaviti kod više od 1 na 10 osoba) nastajali u bolesnika koji su uzimali Actos u kombinaciji s inzulinom.
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. 
U PROactive ispitivanju u trajanju od 3,5 godine, 44/870 (5,1%) bolesnica liječenih pioglitazonom doživjelo je prijelom u usporedbi s 23/905 (2,5%) bolesnica liječenih usporednim lijekom.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics. 
Učinak pioglitazona (monoterapija dozom od 45 mg naspram placebo) ispitivao se u malom ispitivanju u trajanju od 18 tjedana u bolesnika sa šećernom bolešću tipa
Investigations weight increased6 
Pretrage povećana tjelesna težina6
3 In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. 
U kontroliranim kliničkim ispitivanjima, incidencija prijavljenih zatajenja srca uz liječenje pioglitazonom bila je podjednaka onoj u skupinama koje su primale placebo, metformin ili sulfonilureju, ali povišena kad se pioglitazon primjenjivao u kombiniranoj terapiji s inzulinom.
In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months. 
U placebom kontroliranom ispitivanju, bolesnici s neodgovarajućom kontrolom glikemije usprkos tromjesečnog razdoblja optimizacije inzulina bili su randomizacijom raspodijeljeni u skupinu koja je primala pioglitazon odnosno skupinu koja je primala placebo tijekom 12 mjeseci.
Blurred vision due to swelling (or fluid) at the back of the eye has also been reported in patients taking Actos (frequency cannot be estimated from the available data). 
U bolesnika koji uzimaju Actos zabilježen je i zamagljen vid zbog oticanja (ili nakupljanja tekućine) na stražnjoj strani oka (učestalost se ne može procijeniti iz dostupnih podataka).
In PROactive, a cardiovascular outcome study, 5,238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. 
U PROactive ispitivanju kardiovaskularnih ishoda, 5238 bolesnika sa šećernom bolešću tipa 2 i postojećom teškom makrovaskularnom bolešću bilo je randomizacijom raspodijeljeno u skupinu koja je primala pioglitazon i onu koja je primala placebo uz postojeću antidijabetičku i kardiovaskularnu terapiju u trajanju do 3,5 godine.
Each tablet contains 114.51 mg of lactose monohydrate (see section 4.4). 
Jedna tableta sadrži 114,51 mg laktoza hidrata (vidjeti dio 4.4).
− The active substance in Actos is pioglitazone. 
Djelatna tvar Actosa je pioglitazon.
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone. 
U usporednim kontroliranim ispitivanjima pioglitazona opažene su slične promjene u bolesnika liječenih metforminom (relativno smanjenje hemoglobina za 3-4% i hematokrita za 3,6-4,1%) i u manjoj mjeri u bolesnika liječenih sulfonilurejom i inzulinom (relativno smanjenje hemoglobina za 1-2% i hematokrita za 1-3,2%).
Each tablet contains 92.87 mg of lactose monohydrate (see section 4.4). 
Jedna tableta sadrži 92,87 mg laktoza hidrata (vidjeti dio 4.4).
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. 
U ispitivanjima kontroliranima aktivnim usporednim lijekom, prosječno povećanje tjelesne težine tijekom monoterapije pioglitazonom iznosilo je 2-3 kg tijekom jedne godine.
Each tablet contains 76.34 mg of lactose monohydrate (see section 4.4). 
Jedna tableta sadrži 76,34 mg laktoza hidrata (vidjeti dio 4.4).
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Actos. 
Karcinom mokraćnog mjehura manje je često (može se pojaviti u do 1 na 100 osoba) nastao u bolesnika koji uzimaju Actos.
How to store Actos 
Kako čuvati Actos
common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon alanine aminotransferase increased7 
često često često često često povišena kreatin fosfokinaza u krvi često povišena laktična dehidrogenaza manje često povišena alanin aminotransferaza nepoznato nepoznato nepoznato nepoznato nepoznato
Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. 
Poboljšava se kontrola glikemije natašte i nakon obroka u bolesnika sa šećernom bolešću tipa
Metabolism and nutrition disorders hypo-glycaemia uncommon very common common appetite increased uncommon 
Poremećaji metabolizma i prehrane hipoglikemija manje često vrlo često često pojačan apetit manje često
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. 
Tijekom terapije pioglitazonom došlo je do malog smanjenja prosječne vrijednosti hemoglobina (relativno smanjenje za 4%) i hematokrita (relativno smanjenje za 4,1%), sukladno hemodiluciji.
4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration. 
Provedena je analiza objedinjenih podataka o prijelomima kostiju kao nuspojavama u randomiziranim, usporednim lijekom kontroliranim, dvostruko slijepim kliničkim ispitivanjima u više od 8100 bolesnika u skupinama liječenima pioglitazonom i 7400 bolesnika u skupinama liječenima usporednim lijekom u trajanju do 3,5 godine.
Adverse reaction Frequency of adverse reactions of pioglitazone by treatment regimen 
Učestalost nuspojava pioglitazona prema režimu liječenja
- if you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Actos - ako ste alergični na pioglitazon ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako imate zatajenje srca ili ste prije imali zatajenje srca.
Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure (see section 4.4). 
Zatajenje srca uz primjenu pioglitazona zabilježeno je nakon stavljanja lijeka u promet, i bilo je češće kad se pioglitazon primjenjivao u kombinaciji s inzulinom ili u bolesnika sa zatajenjem srca u anamnezi (vidjeti dio 4.4).
Allergic reactions have been reported with frequency not known (cannot be estimated from the available data) in patients taking Actos. 
Kod bolesnika koji su uzimali Actos prijavljene su alergijske reakcije s nepoznatom učestalosti (ne može se procijeniti iz dostupnih podataka).
Carmellose calcium Hyprolose 
Laktoza hidrat
Actos 15 mg tablets Actos 30 mg tablets Actos 45 mg tablets 
Actos 15 mg tablete Actos 30 mg tablete Actos 45 mg tablete pioglitazon
Lactose monohydrate Magnesium stearate 
Magnezijev stearat
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. 
Zabilježeno je da istodobna primjena pioglitazona s gemfibrozilom (inhibitor citokroma P450 2C8) rezultira trostrukim povećanjem AUC-a pioglitazona.